Inhibition of endogenous IL-7Rα expression by short-interfering RNA (shRNA) was shown to impair engraftment and progression of IL-7R+ primary human T-ALLs [102], highlighting the relevance that targeting physiological IL-7R signaling may have in future T-ALL therapeutic interventions. Here, IL7R is linked to acute lymphoblastic leukemia.